Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study

By sjmartinez • June 22, 2024

Gebauer K, Spelman L, Yamauchi PS, Bagel J, Nishandar T, Crane M, Kopeloff I, Kothekar M, Yao SL, Sofen HL. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. J Am Acad Dermatol. 2024 Jul;91(1):91-99. doi: 10.1016/j.jaad.2024.03.025. Epub 2024 Mar 28. PMID: 38554938.

Tags: Dermatology, efficacy, itch, Olive View DoM, psoriasis, Publications, safety, scalp, tildrakizumab

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study

Paller AS, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Gold LS, Armstrong AW, Vender RB, Soung J, Pink AE, Cafone J, Edem BE, Reyes-Servin O, Jiang J, Cresswell K, DeKlotz CMC, Miller-Kassamali M, Yang[...]

Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities

Stein Gold L, Sofen HL, Siu K, Syeed S, Edson-Heredia E, Mitchell B, Goddard E, Kranz B, Gillespie-Akar L, Armstrong AW. Real-World Patient and Disease[...]